# Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer

> **NCT05503108** · PHASE3 · SUSPENDED · sponsor: **Leiden University Medical Center** · enrollment: 10 (actual)

## Conditions studied

- Fasting Mimicking Diet
- HER2-negative Breast Cancer
- Hormone Receptor-positive Breast Cancer
- Pathological Complete Response
- Objective Response Rate
- Neoadjuvant Chemotherapy

## Interventions

- **OTHER:** Fasting Mimicking diet program

## Key facts

- **NCT ID:** NCT05503108
- **Lead sponsor:** Leiden University Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2023-03-17
- **Primary completion:** 2024-01-01
- **Final completion:** 2024-01-01
- **Target enrollment:** 10 (ACTUAL)
- **Why stopped:** fultility
- **Last updated:** 2023-11-22

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05503108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05503108, "Fasting Mimicking Diet Program to ImpRovE ChemoTherapy in Hormone Receptor Postive (HR+), HER2- Breast Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05503108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*